Sanofi will acquire TargeGen for as much as $560 million

06/30/2010 | Reuters

Sanofi-Aventis agreed to pay as much as $560 million to acquire TargeGen, a San Diego developer of small-molecule kinase inhibitors designed to treat blood diseases, to boost its pipeline of cancer drugs. Sanofi will pay $75 million at the closing of the deal, which is expected this quarter.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC